Ovarian cancer: daily aspirin may exert protective effect

  • Trabert B & al.
  • J Natl Cancer Inst
  • 31 May 2018

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Women who received aspirin daily/almost daily for at least 6 months had 10% lower risk for ovarian cancer.
  • Those who received acetaminophen almost daily for ≥6 months had a higher risk for serous ovarian cancer.

Why this matters

  • Data available on the association between use of aspirin or other NSAIDs and risk for ovarian cancer are inconsistent.

Study design

  • This study evaluated 758,829 women who reported analgesic use from 13 studies in the Ovarian Cancer Cohort Consortium.
  • Daily/almost daily use, ≥6 days/week; frequent use, ≥4 days/week.
  • Funding: Defense Ovarian Cancer Research Program, Breast Cancer Now, and the Institute of Cancer Research.

Key results

  • 3514 women developed ovarian cancer.
  • Women who reported daily/almost daily aspirin use had a lower risk for ovarian cancer (n=449; HR, 0.90; P=.05) vs infrequent/nonusers.
  • Women who received aspirin daily/almost daily for 6 months to
  • Daily acetaminophen use was associated with elevated risk for serous tumors (n=26; HR, 1.70; 95% CI, 1.14-2.55) vs infrequent/no use.

Limitations

  • Self-reported data.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit